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PI3K–Akt pathwayChaperones are critical for the folding and regulation of a wide array of cellular proteins. Heat Shock Proteins
(Hsps) are the most representative group of chaperones. Hsp90 represents up to 1–2% of soluble protein.
Although the Hsp90 role is being studied in neurodegenerative diseases, its role in neuronal differentiation
remains mostly unknown. Since neuronal polarity mechanisms depend on local stability and degradation, we
asked whether Hsp90 could be a regulator of axonal polarity and growth. Thus, we studied the role of Hsp90
activity in a well established model of cultured hippocampal neurons using an Hsp90 speciﬁc inhibitor, 17-
AAG. Our present data shows that Hsp90 inhibition at different developmental stages disturbs neuronal polarity
formation or axonal elongation. Hsp90 inhibition during the ﬁrst 3 h in culture promotesmultiple axonmorphol-
ogy, while this inhibition after 3 h slows down axonal elongation. Hsp90 inhibition was accompanied by
decreased Akt and GSK3 expression, as well as, a reduced Akt activity. In parallel, we detected an alteration of
kinesin-1 subcellular distribution.Moreover, these effectswere seconded by changes in Hsp70/Hsc70 subcellular
localization that seem to compensate the lack of Hsp90 activity. In conclusion, our data strongly suggests that
Hsp90 activity is necessary to control the expression, activity or location of speciﬁc kinases and motor proteins
during the axon speciﬁcation and axon elongation processes. Even more, our data demonstrate the existence
of a “time-window” for axon speciﬁcation in this model of cultured neurons after which the inhibition of
Hsp90 only affects axonal elongation mechanisms.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Neuronal function depends on the establishment of different mor-
phological and functional differentiated domains: soma, dendrites,
axon and axon initial segment. The morphological differentiation starts
with the speciﬁcation of one of the initial neurites as the axon, and its
subsequent elongation. This process requires the coordinated reorgani-
zation and dynamics of actin and microtubule cytoskeletons [1,2].
Cytoskeleton dynamic behavior is controlled by microﬁlament and mi-
crotubule associated proteins (ABPs or MAPs), as well as, tubulin post-
translational modiﬁcations [2–4]. Different signaling pathways, such
as PI3K pathway are involved in axon speciﬁcation and growth [5], in-
cluding proteins such as Akt, GSK3 [6–8], Par3/Par6, GTPases Rho, Rac
and cdc42. Axonal speciﬁcation appears as a consequence of the local
accumulation of some determined proteins, that implies a ﬁne regula-
tion of its synthesis and local degradation mechanisms. In cultured ratpartment ofMolecular, Cellular
el.: +34 91 5854717.
olecular “Severo Ochoa”, CSIC-
Autónoma de Madrid, 28049
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ights reserved.hippocampal neurons, several proteins, such as Par3 and Par6, Akt,
and ζPKC, are concentrated in tip of the neurite speciﬁed as the axon
and absent from other neurites. Two possible mechanisms have been
proposed to concentrate these proteins at the future axon tip. First, pro-
teins can be speciﬁcally targeted to the axon tip by kinesins. In fact, KIF5
is expressed in several neurites before axon speciﬁcation but appears
selectively accumulated in the emerging axon and absent from the den-
drites when axon is speciﬁed [9]. Second, axon selective accumulation
of these proteins can be the consequence of protein degradation in
other neurites. In this sense, E3-ubiquitin ligase Smurf2 initiates the
degradation of the Rap1b GTPase in all neurites of unpolarized neuron
stage 2, except in the future axon [10] controlling proper neuronal po-
larization. Moreover, the E3-ubiquitin ligase Smurf1 when is phosphor-
ylated by PKA changes substrate afﬁnity contributing to RhoA
degradation and accumulation of the Par6 protein at the axon tip, con-
tributing to axon initiation and proper polarity formation [11].
While transport and degradation mechanisms contribute to neuro-
nal polarization and axon initiation, mechanisms involved in protecting
proteins from degradation have not been studied during neuronal po-
larization and axon growth. Chaperones are general cellular regulators
critical for the folding and regulation of a wide array of cellular proteins.
Their functions include folding and/or stability, intracellular protein
trafﬁcking, translocation, assembly into multi-protein complexes and
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pathways [12–16]. Hsps are the most representative group of chaper-
ones. Among them, Hsp90 is a very abundant protein and may possibly
represent up to 1–2% of soluble protein. Many proteins involved in the
development and maturation of CNS, such as Akt and GSK3, has been
described as Hsp90 clients. In mammals, there is up to four different
Hsp90 homologs: two cytosolic Hsp90 (constitutive and inducible
isoforms), mitochondrial TRAP1 (tumor necrosis factor receptor-
associated protein 1), and the endoplasmic reticulum (ER) associated
GRP94 (94 kDa glucose-regulated protein). Most eukaryotic species
contain at least two genes encoding highly homologous isoforms of
cytoplasmic Hsp90 [12,13].
In central nervous system, Hsp90 is widely expressed in all regions
at the latest stages of gestation and postnatal development. In the
adultmammaliannervous systemand at all stages of postnatal develop-
ment, the Hsp90 constitutively expressed is preferentially localized on
neurons [12,13,17–19]. Most studies regarding the role of Hsp90 in
nervous system have focused on its involvement on neurodegenerative
diseases [20], however its importance in neuron differentiation remains
mostly unknown. Since Hsp90 is expressed preferentially in neurons in
the nervous system from late embryonic differentiation stages [18], and
local stability and degradationmechanisms are responsible for neuronal
polarity establishment and axon outgrowth, we asked whether Hsp90
could be a regulator of axonal polarity and growth. Our study shows
that Hsp90 activity inhibition at different developmental stages disturbs
neuronal polarity formation or axonal elongation in cultured hippocam-
pal neurons. In parallel to these morphological changes, we have ob-
served decreased Akt activity, concomitant with increased GSK3
activity and alteration of subcellular distribution of motor protein KIF
5. Moreover, these effects are seconded by Hsp70/Hsc70 localization
changes that seem to compensate the lack of Hsp90 activity.
2. Materials and methods
2.1. Antibodies
Commercial antibodies against the following proteins were used:
Hsp90α/β, βIII-tubulin from Santa Cruz Biotechnology; Hsp70/Hsc70
from Stressgen; tau1 from Millipore; α-tyrosinated-tubulin from
Sigma; kinesin 5c and MAP2 from Abcam; GSK3α/β from Invitrogen;
pGSK3α/βS9/21, Akt and pAktS473 from Cell Signaling Technology.
2.2. Neuronal cultures and treatment
Neurons were obtained from E17 mouse embryos as described pre-
viously [21]. Brieﬂy, hippocampi and cortex were removed and after
dissection and washing three times in Ca2+ and Mg2+-free Hank's bal-
anced salt solution (HBSS), the tissues were digested for 15 min in the
same solution containing 0.25% trypsin, in the presence of 0.1 mg/ml
DNase I in the case of the cortex. The tissue was then washed three
times in Ca2+ and Mg2+-free HBSS and dissociated with ﬁre-polished
Pasteur pipettes. The cells were counted, resuspended in plating medi-
um (MEM, 10% horse serum, 0.6% glucose) and plated at a density of
5000/cm2 on polylysine-coated coverslips (1 mg/ml) for immuno-
chemistry experiments. Cortical neurons were plated at a density of
200,000/cm2 on 60 mm plates coated with polylysine for biochemical
experiments. Neurons were incubated at 37 °C for 2 h before switching
them to neuronal culture medium (Neurobasal, B-27, glutamax-I). For
the cultures beyond 6 DIV, neurons were plated and transferred to
dishes containing astrocytes, without contact between them.
To analyze the effect of Hsp90 inhibition, the inhibitor 17-
(Allylamino)-17-demethoxygeldanamycin (17-AAG, from Sigma A8476),
diluted in DMSO, was added at the times and concentrations indicated.
Addition times are counted considering time t0 as the moment of
switching cells to neuronal culture medium. Vehicle (0.1% DMSO) was
added to control cells.2.3. Immunocytochemistry
Neurons were ﬁxed in 4% paraformaldehyde for 20 min. Cover-
slips were treated with 50 mM NH4Cl and incubated with 0.22%
gelatin and 0.1% Triton X-100 in PBS for blocking non-speciﬁc
binding. Cells were then incubated with primary antibodies for
1 h at room temperature. The primary antibodies (and dilutions)
were Hsp90 α/β (1/50), Hsp70/Hsc70 (1/100), MAP2 (1/10.000),
tau 1 (1/1000), KIF5C (1/400), and α-tubulin (1/10,000). After
washing, they were incubated with Alexa-Fluor-conjugated sec-
ondary antibodies (1/1000) or Phalloidin-Alexa594 (1/500). The
coverslips were mounted using Fluoromount G (Southern Biotech)
and images acquired on a LSM510 confocal microscope coupled to
an Axiovert 200 M (Zeiss) microscope. Axon length was quantiﬁed
with the NeuronJ program. Images were processed and presented
using Adobe Photoshop and Illustrator CS4.
2.4. Western-blot
Cell extractswere prepared fromhigh density cortical neurons in lysis
buffer containing 20 mM Hepes [pH 7.4], 100 mM NaCl, 100 mM NaF,
1 mM Na3VO4, 1 μM okadaic acid, 5 mM EDTA, 1% Triton X-100 and a
protease inhibitor cocktail (Complete™, Roche). Brieﬂy, the cells were
left for 30 min on ice in lysis buffer and, after adding loading buffer, the
samples were boiled for 10 min and resolved by SDS-PAGE gels and
transferred to nitrocellulosemembranes in the presence of 20%methanol
and 0.1% SDS, and non-speciﬁc signals were blocked incubating with 5%
BSA in PBS and 0.1% Tween-20 (PBS-T) and then probed with primary
antibodies overnight at 4 °C. The primary antibodies were Hsp90 α/β,
βIII-tubulin, Hsp70, GSK3α/β, pGSK3α/βS9/21, Akt and pAktS473. All of
them were used at 1/1000 dilution. After washing, the membranes
were exposed to the corresponding peroxidase-conjugated secondary
antibody (1/5000, Santa Cruz Biotechnology) for 1 h at room tempera-
ture. Antibody binding was visualized by ECL Amersham) and the results
were quantiﬁed with the Image J software. The quantiﬁed values were
normalized to the values obtained for a control antibody to correct for
variation in the amount of total protein loaded.
2.5. Statistical analysis
All experiments were repeated at least three times and the results
are presented as themean ± standard error of themean. Statistical dif-
ferences between experimental conditions were analyzed by unpaired
t-test tool of the SigmaPlot software.
3. Results
3.1. Early expression of Hsp90 in growth cones during
neuronal development
As mentioned in Section 1, Hsp90 is highly expressed in brain from
late embryonic development to adulthood. However, its function during
neuronal development, as well as, that of other chaperones remains
mostly unknown. We asked if Hsp90 may have a role as a chaperone
that protects proteins during neuronal polarization. Thus, we ﬁrst
studied Hsp90 subcellular distribution in cultured hippocampal neu-
rons in different developmental stages, including neurites' growth,
axon elongation and dendrites' development and maturation. Hippo-
campal neurons were ﬁxed at different developmental stages (1, 2, 3,
6, 21 days in vitro, DIV) and stained with antibodies against Hsp90
and MAP2 or the F-actin marker, Phalloidin (Fig. 1A,B). In all stages,
Hsp90 was mostly localized in neuronal soma, showing higher expres-
sion around the nucleus. Hsp90 was also expressed in all the neurites
at 1 DIV, showing a higher Hsp90 expression in their growth cones
identiﬁed by F-actin staining (Fig. 1A). Once the axon is established
and starts its elongation (2DIV), Hsp90 is localized in the axonal growth
Fig. 1. Hsp90 subcellular localization during neuronal polarization and axonal growth. (A) Hippocampal neurons cultured for 1, 2, 3 and 6 days in vitro (DIV). Neurons were ﬁxed and
stained with antibodies against Hsp90 (green) and MAP2 (red, somatodendritic domain) or Phalloidin-Alexa 594 (F-actin marker) to deﬁne the neuronal morphology and structures
(scale bars = 50 μm). Distal regions of axons in 2 and 3 DIV neurons are indicated into gray dashed lines and 2× magniﬁcations of Hsp90 expression (green) in axonal distal regions
are included in the image. Hsp90 expression in axonal tips is indicated as a1–a7 and arrow heads in 6 DIV neurons image. Dendrites are indicated as d1–d3 and red arrows. 4× magniﬁ-
cations of a1 and d3 are shown. (B) Image shows Hsp90 expression in a 21 DIV hippocampal neuron. Dendrites are identiﬁed by MAP2 staining. Scale bar = 20 μm. (C) The graph
represents the Hsp90 expression level increment normalized to βIII-tubulin along neuronal development. Data are normalized to 1 day in vitro normalized expression levels. Data are
expressed as the mean ± s.e.m. of three independent experiments. A representative western blot of total cell extracts obtained from cortical neurons cultured from 1 to 7 DIV is
shown. Samples were incubated with antibodies against Hsp90 (upper blot) and βIII-tubulin as a loading control (lower blot).
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tion). Hsp90 is still associated to other growth cones of other neurites
(future dendrites). After 3 DIV, Hsp90 axonal localization is character-
ized by an increasing proximal to distal gradient, and continues to be
associated to microtubules and F-actin in the growth cone. At later
stages (6DIV), axonal localization of Hsp90 ismainly observed in axonal
growth cones (white arrow heads), keeping a higher concentration in
the somatodendritic domain. In 21 DIV mature neurons Hsp90 expres-
sion was concentrated in soma showing a higher perinuclear density
(Fig. 1B). Interestingly, a faint Hsp90 staining was observed in the
axon initial segment of these neurons, that was absent along the axon.
In view of this Hsp90 expression pattern along neuronal development,
we analyzed Hsp90 expression levels in neurons from the beginning
of their development to 7 DIV (Fig. 1C). We obtained protein extracts
from 3 h and 1, 2, 3, 4 and 7 DIV cultured cortical neurons. Interestingly,
βIII-tubulin normalized Hsp90 expression levels were signiﬁcantly
augmented between 3 h and 1 DIV (p = 0.029). Hsp90 expression
levels in later stages were increased, around 20%, without any signiﬁ-
cant change compared to 1 DIV neurons (Fig. 1C).
The earlier Hsp90 expression and increment during neuronal devel-
opment, as well as, its presence in the growth cones of all neurites at 1
DIV, when neuronal polarization mechanisms are in place, suggest
that Hsp90 may have a relevant role in the decision of neuronal polari-
zation, as well as in axonal elongation due to microtubules and F-actin
colocalization with Hsp90 in axon growth cone.
3.2. Hsp90 activity is necessary for proper neuronal polarization and
axonal elongation
Then, we analyzed whether Hsp90 activity inhibition may inter-
fere with axon speciﬁcation and/or elongation. A previous studydemonstrated that axon speciﬁcation and neuronal polarization
occurs during the ﬁrst 24 h [7], when our study shows a signiﬁcant
change in Hsp90 expression levels. Hence, we studied the morphol-
ogy and polarization of cultured hippocampal neurons at 3 DIV
with or without the previous addition of an Hsp90 speciﬁc inhibitor
at different times to analyze the consequences of Hsp90 lack of
function (Fig. 2C). Neurons were treated with 17-AAG (10 μM)
when mediumwas changed to neuronal medium from plating medi-
um (0 h) or 3, 6 or 24 h later (Fig. 2A,B). Neurons were then kept till
3 DIV and stained with axonal (tau-1) and somatodendritic (MAP2)
markers. First, we quantiﬁed the number of tau-1 positive axons per
neuron (Fig. 2D). As expected, most control hippocampal neurons in
culture (80.02 ± 1.31%) are polarized showing a single tau-1-positive
process and only 15.91 ± 1.42% of neurons have more than one axon.
Interestingly, Hsp90 inhibition at the time of switching to neuronalme-
dium (0 h) resulted in a signiﬁcant percentage of neuronswithmultiple
tau-1 positive processes ormultiple axonmorphology (57.01 ± 1.95%).
Similar results were obtained when Hsp90 was inhibited 3 h later
(51.81 ± 2.77%). However, when Hsp90 was inhibited at 6 h of culture
in neuronal medium only 26.74 ± 2.47% of neurons showed a multiple
axon pattern. Similar resultswere obtainedwhen inhibitionwas carried
out after 24 h (22.62 ± 4.23%). In all conditions, the percentage of
non-polarized neurons without detectable axon was limited and
did not differ from that observed in control neurons (4.06 ± 0.91%).
Interestingly, the percentage of neurons showing only one axon aug-
mented from 35.34 ± 2.50 when hsp90 was inhibited at 0 h to
71.67 ± 3.35% or 73.76 ± 3.01% after inhibition at 6 or 24 h (Fig. 2D).
Thus, our results suggest that Hsp90 activity is necessary for proper
neuronal polarization at least during the ﬁrst 3 h in culture.
Next, we analyzed whether Hsp90 activity may be involved in the
regulation of axonal elongation once the axon is speciﬁed. Thus, we
Fig. 2.Hsp90 inhibition disrupts neuronal polarization and slows down axonal elongation in different stages of hippocampal neuron development. (A,B) Hippocampal neurons cultured in
the presence or absence of 17-AAG 10 μM, added at different times after switching to neuronal medium and kept in culture for 3 days in vitro. Neurons were ﬁxed and stained with
antibodies against tau-1 (green, axon) andMAP2 (red, somatodendritic domain) to deﬁne the neuronalmorphology and quantify axon length and number. Scale bars = 50 μm. (C) Schema
represents a 3 day time bar and the time of Hsp90 inhibition for each condition. After switching to neuronal medium, the Hsp90 inhibitor, 17-AAG, was added at time 0, 3, 6 or 24 h. Then
neurons were kept till 3 DIV before ﬁxation (PFA 4%). (D) Graph represents the percentage of neurons, shown in A and B, extending one, multiple or without axons. The percentage distri-
bution in cultured control neurons are shown in the gray column. Data are themeans ± s.e.m. from three independent experiments and a minimum of 50 neurons analyzed in each exper-
iment and condition. (E) Graph represents the normalized axonal length of the neurons extending only one axon and treated with 17-AAG (10 μM) at different times. Data are the
means ± s.e.m. from three independent experiments and a minimum of 50 neurons analyzed in each experiment and condition.
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treated with 17-AAG at different times extended signiﬁcantly shorter
axons than control neurons (Fig. 2E).Moreover, axonal length reduction
was correlated to the number of hours that neurons were exposed
to Hsp90 inhibitor. Axons of neurons treated at 0 h had only
25.84 ± 3.28% of the length of control neurons. Axonal length increased
progressivelywhenHsp90was inhibited at 3, 6 or 24 h (37.90 ± 3.28%;
41.35 ± 3.48% or 57.28 ± 7.45%, respectively), compared to 100% in
control neurons. These data demonstrate also a role of Hsp90 in the
regulation of axonal elongation.
3.3. Hsp90 modulates Akt and GSK3 expression and activity in neurons
Some Hsp90 clients have been related to neuronal polarity and axo-
nal elongation. Among them, proteins of the PI3-kinase pathway, such
as Akt or GSK3, are involved in neuronal polarity and axon elongation
mechanisms. Thus, we analyzed whether Akt, GSK3 or their phosphor-
ylated forms could be modiﬁed by the lack of Hsp90 activity during
axon development. High density cultured cortical neuronswere treated
with 17-AAG 10 μM after neuronal medium switching or 24 h later.
Then, protein extracts were obtained and analyzed using antibodies
against Akt, pAkt, GSK3 or pGSK3. Our data show that Akt protein levels
were notably reduced after 17-AAG treatment at 0 h (32.5 ± 9.9%) or24 h (21.6 ± 5.2%) (Fig. 3A). In parallel, the Akt regulatory phosphory-
lation on serine 473 was also reduced at 0 h (38.3. ± 5.0%) or 24 h
(24.8 ± 3.1%). When we analyzed the pAkt/Akt ratio obtained from
neurons treated with 17-AAG at 0 h, a 22.2 ± 6.6% reduction was
detected, reﬂecting a lower Akt activity compared to non-treated neu-
rons. However, only a 6.7 ± 4.8% reduction was detected in neurons
treated at 24 h, which was not signiﬁcantly different compared to
0 hour treatment. These changes in Akt phosphorylation were corrobo-
rated by changes in the phosphorylation of its substrate, GSK3 (Fig. 3B).
GSK3 expressionwas reduced a 31.5 ± 8.1% after treatment at 0 h, and,
in a lesser extent when treatmentwas applied at 24 h (12.6 ± 9.5%). In
both cases, GSK3α/β phosphorylation on serine 21/9 was severely
reduced to 44.6 ± 7.5% or 36.1 ± 5.3% after 0 and 24 hour treatment,
respectively. The analysis of pGSK3S9/21/GSK3 ratio showed a reduction
to values of 47.2 ± 10.6% and 31.8 ± 5.6%, respectively; reﬂecting a
relevant activation of GSK3 at both times. Despite the tendency to a
higher GSK3 activity at 24 h compared to 0 hour treatment, no statisti-
cal difference was found.
3.4. Kinesin-1 distribution is altered by hsp90 inhibition in neurons
The precedent data demonstrate changes in these kinases, but they
are not enough to explain the different neuronal morphology and
Fig. 3. 17-AAGmodiﬁes Akt and GSK3 expression and phosphorylation levels in neurons. (A,B) Quantiﬁcation of Akt and GSK3 expression levels in extracts of cortical neurons cultured in
the absence or presence of 17-AAG (10 μM) from 0 or 24 h till 3 days in vitro. Samples were analyzed by western blot and incubated with antibodies raised against total Akt, pAktS473
(panel A) and GSK3α/β or pGSK3α/βS9/21 (panel B). βIII-tubulin was used as a loading control. Data were normalized to protein/βIII-tubulin control levels. Data are expressed as the
mean ± s.e.m. of three independent experiments. (*p b 0.05; n.s., not signiﬁcant). Representative western-blots are shown below the graphs. The graph on the right on each panel
represents the pAktS473/Akt (panel A) or pGSK3α/βS9/21/GSK3α/β (panel B) ratios of 17-AAG treated neurons at t0 or t24, normalized to control cells (gray dotted line). Note that
decreased phosphorylation levels represent an Akt activity reduction or a GSK3α/β increased activity. Although there are differences between t0 and t24 treatments, any statistical differ-
ence is observed between them.
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studies demonstrate that GSK3 activity is involved in the regulation of
cargo release from kinesins together with Hsc70 [22], which raise the
possibility that local changes in GSK3 activity may modulate axonal
transport. Hence, we established the hypothesis that Hsp90 inhibition
mediated changes in polarity and axonal elongation may be due to
altered kinesin distribution and changes in protein transport and
cargo release. In this sense, kinesin-1 is distributed in all neurites before
polarization to the nascent axon, and is polarized to the neurite that is
speciﬁed as the axon [9]. Thus, we analyzed the distribution of KIF5C
in 3 DIV control neurons or treated with 17-AAG at 3, 6 or 24 h
(Fig. 4). KIF5 was localized in soma, distal axon and axonal growth
cones in control neurons (Fig. 4A). However, KIF5 distribution was
modiﬁed in 3 DIV hippocampal neurons when Hsp90 was inhibited
after 3 h in culture. In this context, KIF5 was detected along the several
axons observed in these neurons, without a distal gradient distribution.
Moreover, KIF5 expression was mostly concentrated in the soma
(Fig. 4B). Hsp90 inhibition after 6 h in culture resulted in KIF5 concen-
tration at the soma, and its absence from axons (Fig. 4C). Finally,neurons treated with 17-AAG after 24 h in culture showed the same
pattern in soma, but KIF5 staining was detected in axonal growth cone
in a lesser extent than in control neurons (Fig. 4D). Hence, changes in
polarity and axonal elongation induced by early Hsp90 inhibition are
conﬁrmed by the modiﬁcations observed in kinesin-1 neuronal
distribution.
3.5. Hsp90 inhibition alters Hsc70/Hsp70 expression levels and location
As mentioned in Section 3.4, another member of the chaperone
protein family, Hsc70, is also involved in cargo release from kinesins.
Thus, we analyzed whether Hsp90 inhibition may affect in some extent
Hsc70 expression or localization. Moreover, in some cell systems the
blocking of Hsp90 activity causes the up-regulation of other chaperones,
such as Hsp70 (for review see [14,16]). First, using an antibody that
recognizes both Hsc70 and Hsp70, we analyzed Hsc70/Hsp70 expres-
sion levels in 3 DIV neurons treated with the Hsp90 inhibitor at 0 h,
whichmodify neuronal polarization, or 24 h, which affects axonal elon-
gation. Hsc70/Hsp70 expression levels were signiﬁcantly increased
Fig. 4. The kinesin-1 KIF5C localization is sensitive to Hsp90 inhibition in hippocampal neurons. 3 DIV hippocampal neurons cultured in the absence (A) or presence of 17-AAG (10 μM),
added at 3 (B), 6 (C) or 24 (D) hours after switching to neuronalmedium.Neuronswereﬁxed and stainedwith antibodies against KIF5C (green) andα-tubulin (red) to deﬁne the neuronal
morphology. Scale bar = 50 μm. Head arrows indicate the KIF5C expression in the distal region of axon and growth cones. Boxes show 2× image magniﬁcation. Note the expression
of KIF5C in the several axons generated after Hsp90 inhibition at 3 h, the absence of KIF5C expression in axon growth cones of neurons treated at 6 h, and the partial recovery of KIF5C
expression in axon growth cones when neurons were treated at 24 h.
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11.40%, respectively) (Fig. 5C). Then, we analyzed Hsp90 and Hsc70/
Hsp70 localization in control and treated neurons. Hsp90 localization
was unaltered by 17-AAG treatment in all conditions compared to
control neurons, and most staining was observed in soma and distal
region of axons (Fig. 5A). In contrast, to the neuronal soma expression
of Hsp90, Hsc70/Hsp70 was not detected in neuronal somas and was
mainly expressed in neuronal processes in control neurons (Fig. 5B).
Same Hsc70/Hsp70 expression pattern was observed when Hsp90 was
inhibited at 24 h. Interestingly, Hsp90 inhibition at 0 h did alter
Hsc70/Hsp70 distribution in neurons, which was concentrated in
neuronal somas and the several axonal processes.
These data may suggest that the lack of Hsp90 activity before axon
speciﬁcation is in somehow compensated by changes in Hsc70/Hsp70
expression and location, taking Hsc70/Hsp70 the position of Hsp90.
However, Hsc70/Hsp70 up-regulation or modiﬁed distribution did not
compensate for the morphological changes generated by Hsp90 inhibi-
tion. Thus, while different chaperones can compensate each other
functions in some cell types [23,24], in neurons Hsc70/Hsp70 is unable
to compensate Hsp90 functions in axonal polarization.
4. Discussion
Our results show a role for Hsp90 during axonal polarization process
and subsequent axonal elongation. Hsp90 activity inhibition before
axon speciﬁcation generates a multiple axon morphology in cultured
hippocampal neurons. Once the axon is speciﬁed and neuronal polarity
achieved, Hsp90 inhibition diminish axonal elongation rate. In both
cases, Akt and GSK3 expression and activity are modiﬁed and the
distribution of motor proteins, such as kinesin-1, is altered. Finally,
Hsp90 inhibition increases the expression of Hsc70/Hsp70 chaperones.
Interestingly, a change in Hsc70/Hsp70 distribution is correlated with
multiple axon morphology.
Hsp90 function in neuronal development has been poorly studied.
Besides the known expression of heat shock proteins (Hsps) in the
neural tube from early mouse embryonic tissue (E9.5), the role of
Hsps during neuronal differentiation is unknown. Hsp90β and
Hsp90α are widely distributed in βIII-tubulin positive cells after E15.5,
suggesting that Hsp90s may be required for speciﬁc functions inneurons [18]. In fact, Hsp90 mediates neurites' outgrowth in PC12
cells [25]. Our results demonstrate that Hsp90 function is necessary to
acquire a proper neuronal polarization with a unique axon. Moreover,
Hsp90 activity is necessary in later stages to promote axonal elongation.
In this sense, differentiation of P19 cells to neurons is accompanied by a
six time increment of Hsp90 expression that is localized in soma and
neurites [26]. We also observed an increment of Hsp90 expression in
hippocampal neurons during the early stage of neuronal polarization
thatwas also previously described during theﬁrst 3 h of N2Aneuroblas-
toma differentiation in response to FK506 treatment [27]. Concomitant-
ly, FK506 treatment of hippocampal neurons increases the expression in
axons of the Hsp90 associated protein FKBP52. Regarding the Hsp90
location in neurites' tips in our experiments, same location was previ-
ously observed in differentiating N2A neuroblastoma cells [27,28].
These data suggest a role of Hsp90 in the modulation of neurites'
growth, and raise the question whether Hsp90 function in one of the
neurites or absence of function in the other neurites' controls axonal
polarization? In fact, our experiments show that Hsp90 inhibition gen-
erates multiple axons, demonstrating that Hsp90 activity is necessary
for axonal polarization. This morphological pattern in neurons has
been previously described after GSK3 inhibition [29,30] or Akt activa-
tion [6]. However, opposite results demonstrating that GSK3 inhibition
does not generate multiple axon morphology have been obtained by
other groups [7,8,31,32]. Nevertheless, these data indicate an important
role of these kinases in axon speciﬁcation and development. In fact, our
data show that Hsp90 inhibition decreases GSK3 and Akt expression
levels, and affect their activities. The Akt activity was reduced and con-
comitantly GSK3 activity was enhanced, as inferred from the pGSK3/
GSK3 ratio. Hsp90 inhibition at time 0 increases GSK3 activity around
50%, and it is tempting to propose that this increment may be responsi-
ble for themultiple axonmorphology. However, GSK3 inhibition did not
reverse the multiple axon morphology generated by Hsp90 inhibition,
but impaired axon outgrowth (data not shown). Several studies have
shown that active Akt (pAkt) is accumulated at the axon growth cone
during axon speciﬁcation [33]. Moreover, Akt inhibition increases its
ubiquitination and degradation [6]. This process is controlled in neu-
rons, where neuronal polarity requires dendritic Akt degradation by
the ubiquitin–proteosome system. According to these data, expression
of constitutively active Akt generates multiple axons [6]. Previous
Fig. 5. Hsp70/Hsc70 expression and localization is altered by Hsp90 inhibition. 3 DIV hippocampal neurons were cultured in the absence or presence of the Hsp90 inhibitor 17-AAG
(10 μM), added at the moment of neuronal medium switching (0 h) or after 24 h. (A) Neurons were ﬁxed and stained with antibodies against Hsp90 (green) and α-tubulin (red, in
white boxes). Scale bar = 50 μm. Note the absence of changes in Hsp90 localization. (B) Neurons in the same experiments were stained with antibodies against Hsp70/Hsc70 to analyze
their localization. Neuronal morphology and integrity were conﬁrmed in images obtained by differential interference contrast, DIC. Scale bars = 50 μm. (C) Cell extracts were obtained
from 3 DIV cultured cortical neurons previously exposed to the Hsp90 inhibitor, 17-AAG (10 μM), at 0 or 24 h. Bottom panel shows a representativewestern-blot of Hsp70/Hsc70 expres-
sion in different experimental conditions. βIII-tubulin was used as a loading control. Graph (upper panel) represents the mean ± s.e.m. Hsp70/Hsc70 of three independent experiments
normalized to βIII-tubulin levels. ***p b 0.001, **p b 0.01.
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activity of GSK3β and Akt [34]. Thus, differential regulation of Akt or
GSK3 stability through Hsp90 in dendrites and axon maybe control
the process of neuronal polarization. However, our data strongly
suggest that is not a question of a simple Akt activity reduction, because
the inhibition of Akt (data not shown) or the elimination of some Akt
isoforms [35] did not generate a loss of axonal polarization. Comple-
mentary to this effect we cannot discard that other Hsp90 clients may
be additionally affected contributing to the ﬁnal polarization effect.
On the other hand, our results show that Hsp90 function is necessary
for proper axonal elongation once the axon is speciﬁed. Hsp90 inhibi-
tion after axon speciﬁcation slows down axonal growth, which may
be in agreement with a reduced contribution of Akt activity [35]. Evalu-
ating this data, it is tantalizing to propose that in this hippocampal
polarization model exists a time-window for axonal speciﬁcation. In
fact, the inhibition during the initial hours affects polarity.
Besides different kinases involved in neuronal polarization and
axonal growth, it has been described that KIF5, kinesin-1, is one of the
ﬁrst proteins to be polarized to the newly speciﬁed axon [9]. In fact,
axonal growth requires a continued input of proteins from soma to
axon that is mediated by motor proteins, such as kinesins [36]. Our
results show that KIF5 is expressed in axon tips and shows an
increasing distal gradient in the axon in control neurons, but afterHsp90 inhibition KIF5 is retained in the soma, highly reduced in
axon tips and in the case of multiple axons KIF5 staining is higher
in the proximal region of the axons. These data prompt to modiﬁca-
tions in protein transport mechanisms and/or the supporting struc-
tures for kinesin movement and polarization. It has been proposed
that cargo liberation from kinesins is mediated by GSK3 phosphory-
lation of the kinesin light chain, which renders kinesins more acces-
sible to Hsc70 chaperone and eases the delivery of its cargo in the
axonal domain [37]. In fact, our data show that Hsp90 inhibition in-
creases GSK3 activity, which may explain the reduced axonal growth
through early cargo liberation before reaching its ﬁnal destination.
Finally, our results show a higher Hsc70 expression both time 0
and 24 h, which would support a disrupted transport of proteins to
axon. The increased Hsc70 could provoke, combined with the high
GSK3 activity, the delivery of kinesin cargos without arriving to its
speciﬁc destination. Besides the increased Hsc70 expression, Hsc70
location was also modiﬁed. Hsc70 remains concentrated in soma
when the Hsp90 inhibitor is applied at the ﬁrst hours after platting,
resembling what happens with KIF5 distribution. The apparent
Hsp90 compensation by Hsc70/Hsp70 could be a cellular strategy
to achieve neuronal polarization in the absence of Hsp90 function.
In fact, previous studies have shown that pharmacological Hsp90
inhibition increases the expression of Hsp70 and Hsp40 to compensate
252 M.J. Benitez et al. / Biochimica et Biophysica Acta 1843 (2014) 245–252for Hsp90 through the activation of a transcription factor, HSF1 [38].
HSF1 is ﬁnely regulated during the neuronal differentiation of
NG108-15 neuroblastoma–glioma hybrid cells to change the pattern
of Hsps and the constitutive Hscs. This differentiation is co-related to
an increased Hsc70 expression [39].
In conclusion, we have described for the ﬁrst time a critical role for
Hsp90 in axonal polarization mechanisms and the subsequent axonal
growth. The effects may be due to the reduction of expression of some
Hsp90 clients, as well as, to anomalous local distribution of proteins at
theﬁrst differentiation stages. Further experiments and new experimen-
tal tools regarding Hsp90 will be necessary to fully understand the
involvement of this chaperone in neuronal polarity and axon growth.
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